According to the group’s soon-to-depart chief scientific officer, Mikael Dolsten, Pfizer has a “robust pipeline” of three clinical and several preclinical candidates. While danuglipron has ...

and after Pfizer chief scientific officer and president of R&D Mikael Dolsten also announced his intention to step down in the next few months after a successor is appointed. Parsey joined Gilead ...

Pharmaceutical giant Pfizer (NYSE: PFE) stands out in this context. The company currently offers a mouthwatering 5.7% dividend yield-- the highest among major drug manufacturers and one of the ...

We came across a bullish thesis on Pfizer Inc. (PFE) on gurufocus by Akim Guerreiro. In this article we will summarize the bulls’ thesis on PFE. Pfizer Inc. share was trading at $29.16 as of ...

Sept. 14 (UPI) --A drug that could reduce the risk of death in cancer patients is showing good promise during its second phase of clinical tests, drugmaker Pfizer announced Saturday. The ...

Pfizer Inc.’s experimental drug for cancer weight loss was shown to help patients regain weight in a mid-stage study, offering fresh promise for treating the dangerous muscle-wasting condition.

NEW YORK (Reuters) - Pfizer is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug Braftovi, which the pharmaceutical maker anticipates ...

(RTTNews) - Pfizer Inc. (PFE) said Saturday that its Phase 2 study of ponsegromab, a monoclonal antibody directed against growth differentiation factor-15 (GDF-15), met its primary endpoint of ...

(RTTNews) - Pfizer Inc. (PFE) announced longer-term follow-up results from the Phase 2 single-arm PHAROS clinical trial evaluating the efficacy and safety of BRAFTOVI (encorafenib) in combination ...

Treatment related adverse events occurred in 8.9% of patients taking placebo and 7.7% of patients taking ponsegromab.i Based on these positive results, Pfizer is discussing late-stage development ...